Abcellera Biologics Earnings Estimate
| ABCL Stock | USD 3.10 0.16 5.44% |
Abcellera Biologics Revenue Breakdown by Earning Segment
By analyzing Abcellera Biologics' earnings estimates, investors can diagnose different trends across Abcellera Biologics' analyst sentiment over time as well as compare current estimates against different timeframes. The value of Gross Profit is estimated to slide to about 31.5 M. Pretax Profit Margin is expected to rise to -7.59 this year
Abcellera | Build AI portfolio with Abcellera Stock |
Abcellera Biologics Earnings Estimation Breakdown
The calculation of Abcellera Biologics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Abcellera Biologics is estimated to be -0.15875 with the future projection ranging from a low of -0.1625 to a high of -0.155. Please be aware that this consensus of annual earnings estimates for Abcellera Biologics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.16 Lowest | Expected EPS | -0.15 Highest |
Abcellera Biologics Earnings Projection Consensus
Suppose the current estimates of Abcellera Biologics' value are higher than the current market price of the Abcellera Biologics stock. In this case, investors may conclude that Abcellera Biologics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Abcellera Biologics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 8 | 50.0% | 0.0 | -0.15875 | -0.57 |
Abcellera Biologics Earnings per Share Projection vs Actual
Actual Earning per Share of Abcellera Biologics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Abcellera Biologics predict the company's earnings will be in the future. The higher the earnings per share of Abcellera Biologics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Abcellera Biologics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Abcellera Biologics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Abcellera Biologics should always be considered in relation to other companies to make a more educated investment decision.Abcellera Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Abcellera Biologics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
2025-11-06 | 2025-09-30 | -0.14 | -0.19 | -0.05 | 35 | ||
2025-08-07 | 2025-06-30 | -0.14 | -0.12 | 0.02 | 14 | ||
2025-05-05 | 2025-03-31 | -0.17 | -0.15 | 0.02 | 11 | ||
2025-02-18 | 2024-12-31 | -0.1471 | -0.12 | 0.0271 | 18 | ||
2024-11-04 | 2024-09-30 | -0.15 | -0.17 | -0.02 | 13 | ||
2024-08-06 | 2024-06-30 | -0.14 | -0.13 | 0.01 | 7 | ||
2024-05-07 | 2024-03-31 | -0.17 | -0.14 | 0.03 | 17 | ||
2024-02-20 | 2023-12-31 | -0.13 | -0.17 | -0.04 | 30 | ||
2023-11-02 | 2023-09-30 | -0.13 | -0.1 | 0.03 | 23 | ||
2023-08-03 | 2023-06-30 | -0.13 | -0.11 | 0.02 | 15 | ||
2023-05-04 | 2023-03-31 | -0.14 | -0.14 | 0.0 | 0 | ||
2023-02-21 | 2022-12-31 | -0.01 | -0.1 | -0.09 | 900 | ||
2022-11-08 | 2022-09-30 | 0.05 | 0.08 | 0.03 | 60 | ||
2022-08-09 | 2022-06-30 | -0.02 | -0.02 | 0.0 | 0 | ||
2022-05-10 | 2022-03-31 | 0.38 | 0.54 | 0.16 | 42 | ||
2022-02-24 | 2021-12-31 | 0.19 | 0.19 | 0.0 | 0 | ||
2021-11-09 | 2021-09-30 | -0.05 | -0.08 | -0.03 | 60 | ||
2021-08-12 | 2021-06-30 | 0.08 | -0.01 | -0.09 | 112 | ||
2021-05-13 | 2021-03-31 | 0.38 | 0.37 | -0.01 | 2 | ||
2021-03-29 | 2020-12-31 | 0.61 | 0.44 | -0.17 | 27 | ||
2020-12-14 | 2020-09-30 | -0.02 | -0.04 | -0.02 | 100 | ||
2020-06-30 | 2020-03-31 | 0 | 0.0102 | 0.0102 | 0 | ||
2020-03-31 | 2019-12-31 | 0 | 0.0102 | 0.0102 | 0 | ||
2019-12-31 | 2019-09-30 | 0 | -0.0108 | -0.0108 | 0 | ||
2019-09-30 | 2019-06-30 | 0 | 2.0E-4 | 2.0E-4 | 0 | ||
2019-06-30 | 2019-03-31 | 0 | -0.002 | -0.002 | 0 | ||
2019-03-31 | 2018-12-31 | 0 | -0.002 | -0.002 | 0 |
About Abcellera Biologics Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Abcellera Biologics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Abcellera Biologics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Abcellera Biologics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | 134.5 M | 188.2 M | |
| Retained Earnings Total Equity | 490.1 M | 381.6 M | |
| Earnings Yield | (0.22) | (0.21) | |
| Price Earnings Ratio | (6.09) | (5.79) | |
| Price Earnings To Growth Ratio | (0.78) | (0.74) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abcellera Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services. For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Abcellera Biologics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.459 | Earnings Share (0.57) | Revenue Per Share | Quarterly Revenue Growth 0.376 | Return On Assets |
Understanding Abcellera Biologics requires distinguishing between market price and book value, where the latter reflects Abcellera's accounting equity. The concept of intrinsic value - what Abcellera Biologics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Abcellera Biologics' price substantially above or below its fundamental value.
Understanding that Abcellera Biologics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Abcellera Biologics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Abcellera Biologics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.